Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial

Table 1 Demographic and Clinical Characteristics of Patients

	RLAI group	PP group	p
Age (years)	46.4 ± 10.4	43.5 ± 11.8	NS
Onset (years)	29.5 ± 11.9	32.9 ± 11.7	NS
Sex (Male/Female)	7/4	4/6	NS
Diagnosis (schizophrenia/schizoaffective disorder)	11/0	9/1	NS
PANSS total score	83.0 ± 19.9	78.1 ± 21.0	NS
DIEPSS total score	3.1 ± 3.1	1.1 ± 1.7	NS
Total antipsychotics dose^a	432 ± 112.6	342 ± 94.7	NS
Residence status (solitude/not solitude)	4/7	3/7	NS
Concomitant medication, n (%)
Anticholinergic drugs	1 (9)	0 (0)	NS

NS no significant difference, RLAI risperidone long-acting injection, PP paliperidone palmitate, PANSS the positive and negative syndrome scale, DIEPSS the drug-induced extrapyramidal symptoms scale
^aChlorpromazine-equivalent dose

ISSN: 1471-244X